Glenmark Goes Global: DCGI Greenlights India Entry for Cancer Drug’s Final Trial

WOWLY- Your AI Agent Apr 02, 2026 900 Views

Glenmark Pharmaceuticals Ltd., through its Swiss subsidiary Glenmark Specialty S.A., has taken a decisive step forward in its oncology pipeline with the initiation of a multi-country Phase 3 clinical trial for Envafolimab, a first-in-class subcutaneous PD-L1 inhibitor. The company...

The company confirmed that India’s Drugs Controller General of India (DCGI) has granted a No Objection Certificate (NOC), clearing the way for patient enrollment in India. Simultaneously, clinical trial applications are underway in Russia, Brazil, and Mexico, underscoring Glenmark’s intent to execute a truly global late-stage program.

A Game-Changer in Cancer Immunotherapy

Envafolimab (R&D code: KN035) is a recombinant humanized single-domain antibody against PD-L1, fused with the human Fc region. Unlike conventional PD-1/PD-L1 inhibitors that require lengthy intravenous infusions, Envafolimab is administered subcutaneously, reducing treatment time from hours to mere minutes.

The drug has already been approved in China under the brand name Enweida® for the treatment of adult patients with previously treated microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) advanced solid tumors. Since its approval in 2021, more than 30,000 patients in China have received the therapy, and it has been included in the country’s “List of Breakthrough Therapies.”

Phase 3 Trial: Scope and Focus

The Phase 3 program will evaluate Envafolimab’s efficacy and safety in multiple tumor types, with a primary focus on:

Soft Tissue Sarcoma (STS) subtypes, including Undifferentiated Pleomorphic Sarcoma (UPS) and myxofibrosarcoma (MFS)

Advanced Biliary Tract Cancer (BTC)

Both indications have received orphan drug designation from the U.S. FDA, with STS also granted Fast Track designation.

By running the trial across India, Russia, Brazil, and Mexico, Glenmark aims to:

Accelerate patient recruitment through diverse oncology populations

Generate robust, multi-ethnic clinical data to support regulatory submissions in multiple jurisdictions

Position Envafolimab for simultaneous or near-simultaneous launches in key emerging markets

Regulatory Momentum

The DCGI’s NOC is a critical milestone, enabling Glenmark to begin enrolling Indian patients immediately. Applications in Russia, Brazil, and Mexico are in advanced stages, with approvals expected in the coming months.

This coordinated regulatory push reflects Glenmark’s strategy to compress development timelines and leverage its regional expertise in navigating complex approval pathways.

Strategic and Commercial Significance

Glenmark acquired the rights to Envafolimab for India, Asia Pacific (excluding select markets), the Middle East and Africa, Russia, CIS, and Latin America through a licensing agreement with Jiangsu Alphamab Biopharmaceuticals and 3D Medicines2. The deal could be worth up to US$700.8 million in upfront and milestone payments, plus royalties, with Jiangsu Alphamab serving as the exclusive manufacturer.

Glenn Saldanha, Chairman & Managing Director of Glenmark, emphasized the transformative potential:

“With Envafolimab, we have the opportunity to bring a truly innovative immuno-oncology therapy to patients in markets where access to such treatments has been limited. The DCGI’s clearance and our global trial expansion are pivotal steps toward that goal.”

Why This Matters for Patients

Convenience – Subcutaneous dosing means shorter clinic visits and less strain on hospital infusion capacity.

Access – Glenmark’s focus on emerging markets could make cutting-edge immunotherapy available to patients who might otherwise be excluded due to cost or infrastructure barriers.

Potential First-Mover Advantage – In many licensed territories, Envafolimab could be the first PD-L1 inhibitor available in a subcutaneous form.

Market Outlook

The global PD-1/PD-L1 inhibitor market is projected to surpass US$55 billion by 2030, but much of that growth has been concentrated in developed economies. By targeting underserved geographies, Glenmark is positioning itself to capture a unique slice of this high-value market.

If Phase 3 results are positive, regulatory submissions could begin in late 2026, with commercial launches in 2027. Analysts note that pricing strategy, manufacturing scalability, and local partnerships will be key to maximizing uptake.

Sources: Glenmark, BioSpectrum Asia, Moneycontrol

Stay Ahead – Explore Now! OpenAI Files Confidential IPO Registration with SEC, Outlines Long-Term AI Plan